Invida Announces Acquisition of Dermatology and Primary Care Product Portfolios in India
by RealPTC Expert
Invida Holdings Private Limited, the leading specialty biopharmaceutical company focused on the commercialization of healthcare brands throughout Asia Pacific, announced the acquisition of a brand portfolio from India-based Shalaks Pharmaceuticals Pvt Ltd. No financial terms of the acquisition were disclosed. Upon acquisition of the product portfolio from Shalaks, Invida will market the products under the Invida brand.
Invida will focus its sales and marketing efforts on high volume dermatology brands in key growth segments, including topical anti-acne, anti-fungal, sun screens, anti-scar, anti-pigmentation and moisturizers.
The Indian pharmaceutical market is currently valued at USD 10 billion. It is one of the fastest growing pharmaceutical markets in the world and is forecasted to grow in double-digits in medium term. The Indian dermatology market, valued at USD 513 million, grew by 21% in 2010 and represents 25% of the Asia-Pacific dermatology market with a CAGR of 15% (2005-2010) and is a significant growth driver of the Indian pharmaceutical market.
Other companies have shown interest in the Indian pharmaceutical market: AB SCIEX, a global leader in life science analytical technologies, and Leica Microsystems, a world leading provider of microscopy systems and total histology solutions, yesterday announced that they have acquired Labindia's divisions, respectively mass spectrometry division and microscopy and histopathology divisions.
Subscribe to:
Post Comments (Atom)
0 comments:
Leave a Comment